---
figid: PMC3765962__gr2
figtitle: Important molecular pathways and drug targets in RCC
organisms:
- NA
organisms_ner:
- Homo sapiens
- Danio rerio
pmcid: PMC3765962
filename: gr2.jpg
figlink: /pmc/articles/PMC3765962/figure/f0010/
number: F2
caption: Important molecular pathways and drug targets in RCC. Inactive VHL leads
  to increased concentrations of HIF-alpha subunits. The PI3K/mTOR pathway also increases
  expression of HIF-alpha subunits. The resulting transcriptional stimulation of the
  HIF response element HRE and the rise in VEGF production stimulates endothelial
  growth and increased vascular supply to the tumor. Targeted therapies inhibit a
  variety of molecules along the involved signaling cascades in both tumor and endothelial
  cells. VHL,Von Hippel Lindau; HIF, hypoxia-induced factor; HRE, HIF response element;
  VEGF, vascular endothelial growth factor; mTOR, mammalian target of rapamycin; MAPK,
  mitogen-activated protein kinase. Adapted with permission of Future Medicine Ltd.
papertitle: Adjuvant Therapy in Renal Cell Carcinomaâ€”Past, Present, and Future.
reftext: Tobias Janowitz, et al. Semin Oncol. 2013 Aug;40(4):482-491.
year: '2013'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9636176
figid_alias: PMC3765962__F2
figtype: Figure
redirect_from: /figures/PMC3765962__F2
ndex: ae59e74e-ded1-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3765962__gr2.html
  '@type': Dataset
  description: Important molecular pathways and drug targets in RCC. Inactive VHL
    leads to increased concentrations of HIF-alpha subunits. The PI3K/mTOR pathway
    also increases expression of HIF-alpha subunits. The resulting transcriptional
    stimulation of the HIF response element HRE and the rise in VEGF production stimulates
    endothelial growth and increased vascular supply to the tumor. Targeted therapies
    inhibit a variety of molecules along the involved signaling cascades in both tumor
    and endothelial cells. VHL,Von Hippel Lindau; HIF, hypoxia-induced factor; HRE,
    HIF response element; VEGF, vascular endothelial growth factor; mTOR, mammalian
    target of rapamycin; MAPK, mitogen-activated protein kinase. Adapted with permission
    of Future Medicine Ltd.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - VHL
  - HIF1A
  - EPAS1
  - HIF3A
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MTOR
  - ARNT
  - AKT1
  - AKT2
  - AKT3
  - PGK1
  - SLC2A3
  - FGF1
  - FGF2
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FGF10
  - FGF11
  - FGF12
  - FGF13
  - FGF14
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - EPO
  - TIMP1
  - EPX
  - PLAU
  - PRAP1
  - LDHA
  - SLC2A1
  - HK2
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - FLT1
  - KDR
  - FLT4
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - vhl
  - mtor
  - pgk1
  - epoa
  - ldha
  - slc2a1a
  - hk2
  - vegfaa
  - flt1
  - kdr
  - kdrl
  - flt4
  - Temsirolimus
  - Pazopanib
  - Cancer
---
